{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:16:42Z","timestamp":1789715802827,"version":"4.0.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11030-022-10452-2","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T04:02:37Z","timestamp":1653710557000},"page":"729-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["High-throughput virtual screening of small-molecule inhibitors targeting immune cell checkpoints to discover new immunotherapeutics for human diseases"],"prefix":"10.1007","volume":"27","author":[{"given":"Satyendra","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-0596","authenticated-orcid":false,"given":"Vijay Kumar","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"issue":"4","key":"10452_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10452_CR2","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.4049\/jimmunol.1202438","volume":"190","author":"J Illingworth","year":"2013","unstructured":"Illingworth J, Butler NS, Roetynck S, Mwacharo J, Pierce SK, Bejon P, Crompton PD, Marsh K, Ndungu FM (2013) Chronic exposure to plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion. J Immunol 190(3):1038\u20131047","journal-title":"J Immunol"},{"issue":"10","key":"10452_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.micinf.2016.06.003","volume":"18","author":"RM Gon\u00e7alves-Lopes","year":"2016","unstructured":"Gon\u00e7alves-Lopes RM, Lima NF, Carvalho KI, Scopel KK, Kall\u00e1s EG, Ferreira MU (2016) Surface expression of inhibitory (CTLA-4) and stimulatory (OX40) receptors by CD4+ regulatory T cell subsets circulating in human malaria. Microbes Infect 18(10):639\u2013648","journal-title":"Microbes Infect"},{"issue":"10","key":"10452_CR4","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/nm1482","volume":"12","author":"L Trautmann","year":"2006","unstructured":"Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, Routy JP (2006) Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12(10):1198\u20131202","journal-title":"Nat Med"},{"issue":"1","key":"10452_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005349","volume":"12","author":"GM Chew","year":"2016","unstructured":"Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, Hammond KB, Clayton KL, Ishii N, Abdel-Mohsen M, Liegler T (2016) TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection. PLoS Pathog 12(1):e1005349","journal-title":"PLoS Pathog"},{"issue":"1","key":"10452_CR6","doi-asserted-by":"publisher","first-page":"e0146905","DOI":"10.1371\/journal.pone.0146905","volume":"11","author":"KM Pollock","year":"2016","unstructured":"Pollock KM, Montamat-Sicotte DJ, Grass L, Cooke GS, Kapembwa MS, Kon OM, Sampson RD, Taylor GP, Lalvani A (2016) PD-1 expression and cytokine secretion profiles of mycobacterium tuberculosis-specific CD4+ T-cell subsets; potential correlates of containment in HIV-TB co-infection. PLoS ONE 11(1):e0146905","journal-title":"PLoS ONE"},{"issue":"2","key":"10452_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nri.2017.112","volume":"18","author":"MN Wykes","year":"2018","unstructured":"Wykes MN, Lewin SR (2018) Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18(2):91\u2013104","journal-title":"Nat Rev Immunol"},{"issue":"22","key":"10452_CR8","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","volume":"17","author":"EJ Lipson","year":"2011","unstructured":"Lipson EJ, Drake CG (2011) Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17(22):6958\u20136962","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10452_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0300-483X(02)00051-3","volume":"174","author":"T Vial","year":"2002","unstructured":"Vial T, Choquet-Kastylevsky G, Descotes J (2002) Adverse effects of immunotherapeutics involving the immune system. Toxicology 174(1):3\u201311","journal-title":"Toxicology"},{"key":"10452_CR10","unstructured":"The_American_Cancer_Society_medical_and_editorial_content_team, Monoclonal antibodies and their side effects. American Cancer Society, 2019"},{"issue":"2","key":"10452_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1046\/j.1365-2567.2000.00121.x","volume":"101","author":"DM Sansom","year":"2000","unstructured":"Sansom DM (2000) CD28, CTLA-4 and their ligands: Who does what and to whom? Immunology 101(2):169","journal-title":"Immunology"},{"issue":"4","key":"10452_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/intimm\/10.4.499","volume":"10","author":"C Olsson","year":"1998","unstructured":"Olsson C, Micha\u00eblsson E, Parra E, Pettersson U, Lando PA, Dohlsten M (1998) Biased dependency of CD80 versus CD86 in the induction of transcription factors regulating the human IL-2 promoter. Int Immunol 10(4):499\u2013506","journal-title":"Int Immunol"},{"issue":"3","key":"10452_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.185.3.393","volume":"185","author":"PA van der Merwe","year":"1997","unstructured":"van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ (1997) CD80 (B7\u20131) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 185(3):393\u2013404","journal-title":"J Exp Med"},{"issue":"9","key":"10452_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","volume":"1","author":"PS Linsley","year":"1994","unstructured":"Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R (1994) Human B7\u20131 (CD80) and B7\u20132 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1(9):793\u2013801","journal-title":"Immunity"},{"key":"10452_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"10452_CR16","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1002\/eji.200324228","volume":"33","author":"SC Liang","year":"2003","unstructured":"Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, Sharpe AH (2003) Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 33(10):2706\u20132716","journal-title":"Eur J Immunol"},{"issue":"18","key":"10452_CR17","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.3390\/ijms20184654","volume":"20","author":"S Almahmoud","year":"2019","unstructured":"Almahmoud S, Zhong HA (2019) Molecular modeling studies on the binding mode of the PD-1\/PD-L1 complex inhibitors. Int J Mol Sci 20(18):4654","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10452_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141\u2013151","journal-title":"Immunity"},{"issue":"1","key":"10452_CR19","first-page":"96","volume":"8","author":"LA Raedler","year":"2015","unstructured":"Raedler LA (2015) Keytruda (pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma. Am Health Drug Benefits 8(1):96","journal-title":"Am Health Drug Benefits"},{"issue":"6871","key":"10452_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","volume":"415","author":"L Monney","year":"2002","unstructured":"Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, Freeman GJ (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415(6871):536\u2013541","journal-title":"Nature"},{"issue":"3","key":"10452_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf Y, Anderson AC, Kuchroo VK (2020) TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol 20(3):173\u2013185","journal-title":"Nat Rev Immunol"},{"issue":"69","key":"10452_CR22","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/S0959-8049(16)32903-3","volume":"1","author":"A Murtaza","year":"2016","unstructured":"Murtaza A, Laken H, Correia JDS, McNeeley P, Altobell L, Zhang J, Vancutsem P, Wilcoxen K, Jenkins D (2016) Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody. Eur J Cancer 1(69):S102","journal-title":"Eur J Cancer"},{"key":"10452_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ymeth.2018.11.008","volume":"154","author":"C Klein","year":"2019","unstructured":"Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, Uma\u00f1a P (2019) Engineering therapeutic bispecific antibodies using CrossMab technology. Methods 154:21\u201331","journal-title":"Methods"},{"issue":"1","key":"10452_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, Eaton D (2009) The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 10(1):48\u201357","journal-title":"Nat Immunol"},{"issue":"9","key":"10452_CR25","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41587-020-0666-1","volume":"38","author":"E Dolgin","year":"2020","unstructured":"Dolgin E (2020) Antibody engineers seek optimal drug targeting TIGIT checkpoint. Nat Biotechnol 38(9):1007\u20131010","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10452_CR26","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1073\/pnas.0409071102","volume":"102","author":"LC Gonzalez","year":"2005","unstructured":"Gonzalez LC, Loyet KM, Calemine-Fenaux J, Chauhan V, Wranik B, Ouyang W, Eaton DL (2005) A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci 102(4):1116\u20131121","journal-title":"Proc Natl Acad Sci"},{"key":"10452_CR27","doi-asserted-by":"crossref","unstructured":"Rajalingam R (2012) Overview of the killer cell immunoglobulin-like receptor system. Immunogenetics, 391\u2013414","DOI":"10.1007\/978-1-61779-842-9_23"},{"issue":"3","key":"10452_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1365-2567.2010.03398.x","volume":"132","author":"KS Campbell","year":"2011","unstructured":"Campbell KS, Purdy AK (2011) Structure\/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 132(3):315\u2013325","journal-title":"Immunology"},{"key":"10452_CR29","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez F, Taura J, Camacho J, L\u00f3pez-Cano M, Fern\u00e1ndez-Due\u00f1as V, Castro N, Castro J, Ciruela F (2018) PBF509, an adenosine A2A receptor antagonist with efficacy in rodent models of movement disorders. Front Pharmacol, 1200","DOI":"10.3389\/fphar.2018.01200"},{"key":"10452_CR30","doi-asserted-by":"crossref","unstructured":"Furukawa, F. (2018) The Nobel prize in physiology or medicine 2018 was awarded to cancer therapy by inhibition of negative immune regulation. Trends Immunother 2(1)","DOI":"10.24294\/ti.v2.i1.1065"},{"issue":"4","key":"10452_CR31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.gendis.2018.10.003","volume":"5","author":"X Zang","year":"2018","unstructured":"Zang X (2018) 2018 Nobel prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade\u2013a personal account. Genes Dis 5(4):302","journal-title":"Genes Dis"},{"issue":"1","key":"10452_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334","journal-title":"N Engl J Med"},{"key":"10452_CR33","doi-asserted-by":"crossref","unstructured":"Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, Rizvi NA, Lesokhin AM, Atkins MB, Kirkwood JM, Burke MM (2014) Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)","DOI":"10.1093\/annonc\/mdu344.1"},{"issue":"1","key":"10452_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28(1):235\u2013242","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10452_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-35754-0","volume":"8","author":"AK Gandhi","year":"2018","unstructured":"Gandhi AK, Kim WM, Sun ZYJ, Huang YH, Bonsor DA, Sundberg EJ, Kondo Y, Wagner G, Kuchroo VK, Petsko G, Blumberg RS (2018) High resolution X-ray and NMR structural study of human T-cell immunoglobulin and mucin domain containing protein-3. Sci Rep 8(1):1\u201313","journal-title":"Sci Rep"},{"issue":"14","key":"10452_CR36","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1073\/pnas.1120606109","volume":"109","author":"KF Stengel","year":"2012","unstructured":"Stengel KF, Harden-Bowles K, Yu X, Rouge L, Yin J, Comps-Agrar L, Wiesmann C, Bazan JF, Eaton DL, Grogan JL (2012) Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell\u2013cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc Natl Acad Sci 109(14):5399\u20135404","journal-title":"Proc Natl Acad Sci"},{"issue":"16","key":"10452_CR37","doi-asserted-by":"publisher","first-page":"10460","DOI":"10.1074\/jbc.M114.612291","volume":"290","author":"S Moradi","year":"2015","unstructured":"Moradi S, Berry R, Pymm P, Hitchen C, Beckham SA, Wilce MC, Walpole NG, Clements CS, Reid HH, Perugini MA, Brooks AG (2015) The structure of the atypical killer cell immunoglobulin-like receptor, KIR2DL4. J Biol Chem 290(16):10460\u201310471","journal-title":"J Biol Chem"},{"issue":"47","key":"10452_CR38","doi-asserted-by":"publisher","first-page":"39553","DOI":"10.1074\/jbc.M507629200","volume":"280","author":"DM Compaan","year":"2005","unstructured":"Compaan DM, Gonzalez LC, Tom I, Loyet KM, Eaton D, Hymowitz SG (2005) Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex. J Biol Chem 280(47):39553\u201339561","journal-title":"J Biol Chem"},{"issue":"21","key":"10452_CR39","doi-asserted-by":"publisher","first-page":"E4223","DOI":"10.1073\/pnas.1617941114","volume":"114","author":"UA Ramagopal","year":"2017","unstructured":"Ramagopal UA, Liu W, Garrett-Thomson SC, Bonanno JB, Yan Q, Srinivasan M, Wong SC, Bell A, Mankikar S, Rangan VS, Deshpande S (2017) Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proc Natl Acad Sci 114(21):E4223\u2013E4232","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"10452_CR40","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1073\/pnas.0712278105","volume":"105","author":"DYW Lin","year":"2008","unstructured":"Lin DYW, Tanaka Y, Iwasaki M, Gittis AG, Su HP, Mikami B, Okazaki T, Honjo T, Minato N, Garboczi DN (2008) The PD-1\/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci 105(8):3011\u20133016","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"10452_CR41","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.str.2011.06.014","volume":"19","author":"AS Dor\u00e9","year":"2011","unstructured":"Dor\u00e9 AS, Robertson N, Errey JC, Ng I, Hollenstein K, Tehan B, Hurrell E, Bennett K, Congreve M, Magnani F, Tate CG (2011) Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 19(9):1283\u20131293","journal-title":"Structure"},{"issue":"3","key":"10452_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"G Madhavi Sastry","year":"2013","unstructured":"Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27(3):221\u2013234","journal-title":"J Comput Aided Mol Des"},{"issue":"D1","key":"10452_CR43","doi-asserted-by":"publisher","first-page":"D1217","DOI":"10.1093\/nar\/gkx1026","volume":"46","author":"X Zeng","year":"2018","unstructured":"Zeng X, Zhang P, He W, Qin C, Chen S, Tao L, Wang Y, Tan Y, Gao D, Wang B, Chen Z (2018) NPASS: natural product activity and species source database for natural product research, discovery and tool development. Nucleic Acids Res 46(D1):D1217\u2013D1222","journal-title":"Nucleic Acids Res"},{"key":"10452_CR44","unstructured":"Selleckchem, FDA-approved drug library. https:\/\/www.selleckchem.com\/screening\/fda-approved-drug-library.html"},{"key":"10452_CR45","unstructured":"Selleckchem, FDA-approved & passed phase I drug library. https:\/\/www.selleckchem.com\/screening\/fda-approved-passed-phase-i-drug-library.html"},{"issue":"12","key":"10452_CR46","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","volume":"21","author":"JC Shelley","year":"2007","unstructured":"Shelley JC, Cholleti A, Frye LL, Greenwood JR, Timlin MR, Uchimaya M (2007) Epik: a software program for pK a prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des 21(12):681\u2013691","journal-title":"J Comput Aided Mol Des"},{"issue":"2","key":"10452_CR47","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1021\/ci800324m","volume":"49","author":"TA Halgren","year":"2009","unstructured":"Halgren TA (2009) Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 49(2):377\u2013389","journal-title":"J Chem Inf Model"},{"issue":"2","key":"10452_CR48","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1747-0285.2007.00483.x","volume":"69","author":"T Halgren","year":"2007","unstructured":"Halgren T (2007) New method for fast and accurate binding-site identification and analysis. Chem Biol Drug Des 69(2):146\u2013148","journal-title":"Chem Biol Drug Des"},{"key":"10452_CR49","first-page":"6177","volume":"4","author":"EP Glide","year":"2006","unstructured":"Glide EP (2006) Docking and scoring incorporating a model of hydrophobic enclosure for protein\u2212ligand complexes. J Med Chem 4:6177\u20136196","journal-title":"J Med Chem"},{"issue":"21","key":"10452_CR50","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein\u2212ligand complexes. J Med Chem 49(21):6177\u20136196","journal-title":"J Med Chem"},{"issue":"2","key":"10452_CR51","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/prot.10613","volume":"55","author":"MP Jacobson","year":"2004","unstructured":"Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, Friesner RA (2004) A hierarchical approach to all-atom protein loop prediction. Proteins Struct Funct Bioinform 55(2):351\u2013367","journal-title":"Proteins Struct Funct Bioinform"},{"issue":"10","key":"10452_CR52","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1002\/prot.23106","volume":"79","author":"J Li","year":"2011","unstructured":"Li J, Abel R, Zhu K, Cao Y, Zhao S, Friesner RA (2011) The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. Proteins Struct Funct Bioinform 79(10):2794\u20132812","journal-title":"Proteins Struct Funct Bioinform"},{"issue":"8","key":"10452_CR53","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.patrec.2005.10.010","volume":"27","author":"T Fawcett","year":"2006","unstructured":"Fawcett T (2006) An introduction to ROC analysis. Pattern Recogn Lett 27(8):861\u2013874","journal-title":"Pattern Recogn Lett"},{"key":"10452_CR54","doi-asserted-by":"crossref","unstructured":"Naik B, Mattaparthi VSK, Gupta N, Ojha R, Das P, Singh S, Prajapati VK, Prusty D (2021) Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications. J Biomol Struct Dyn 1\u201325","DOI":"10.1080\/07391102.2021.1931451"},{"key":"10452_CR55","unstructured":"WebGRO for macromolecular simulations (https:\/\/simlab.uams.edu\/)"},{"key":"10452_CR56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1","author":"MJ Abraham","year":"2015","unstructured":"Abraham MJ, Murtola T, Schulz R, P\u00e1ll S, Smith JC, Hess B, Lindahl E (2015) GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1:19\u201325","journal-title":"SoftwareX"},{"issue":"8","key":"10452_CR57","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1107\/S0907444904011679","volume":"60","author":"AW Sch\u00fcttelkopf","year":"2004","unstructured":"Sch\u00fcttelkopf AW, Van Aalten DM (2004) PRODRG: a tool for high-throughput crystallography of protein\u2013ligand complexes. Acta Crystallogr D Biol Crystallogr 60(8):1355\u20131363","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"13","key":"10452_CR58","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/jcc.20090","volume":"25","author":"C Oostenbrink","year":"2004","unstructured":"Oostenbrink C, Villa A, Mark AE, Van Gunsteren WF (2004) A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. J Comput Chem 25(13):1656\u20131676","journal-title":"J Comput Chem"},{"key":"10452_CR59","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.biopha.2017.10.001","volume":"96","author":"A Ghorbani","year":"2017","unstructured":"Ghorbani A (2017) Mechanisms of antidiabetic effects of flavonoid rutin. Biomed Pharmacother 96:305\u2013312","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"10452_CR60","doi-asserted-by":"publisher","first-page":"860","DOI":"10.2174\/0929867323666160217124333","volume":"23","author":"S Habtemariam","year":"2016","unstructured":"Habtemariam S (2016) Rutin as a natural therapy for Alzheimer\u2019s disease: insights into its mechanisms of action. Curr Med Chem 23(9):860\u2013873","journal-title":"Curr Med Chem"},{"issue":"9","key":"10452_CR61","doi-asserted-by":"publisher","first-page":"e0237948","DOI":"10.1371\/journal.pone.0237948","volume":"15","author":"CR Rosenberg","year":"2020","unstructured":"Rosenberg CR, Fang X, Allison KR (2020) Potentiating aminoglycoside antibiotics to reduce their toxic side effects. PLoS ONE 15(9):e0237948","journal-title":"PLoS ONE"},{"issue":"3","key":"10452_CR62","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0041-3879(82)80031-7","volume":"63","author":"WE Sanders Jr","year":"1982","unstructured":"Sanders WE Jr, Hartwig C, Schnieder N, Cacciatore R, Valdez H (1982) Activity of amikacin against mycobacteria in vitro and in murine tuberculosis. Tubercle 63(3):201\u2013208","journal-title":"Tubercle"},{"key":"10452_CR63","unstructured":"Clinical Trials.gov, Inulin for infections in the intensive care unit."},{"key":"10452_CR64","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1043-4526(10)60004-6","volume":"60","author":"ED Berry","year":"2010","unstructured":"Berry ED, Wells JE (2010) Escherichia coli O157: H7: recent advances in research on occurrence, transmission, and control in cattle and the production environment. Adv Food Nutr Res 60:67\u2013117","journal-title":"Adv Food Nutr Res"},{"key":"10452_CR65","doi-asserted-by":"publisher","unstructured":"Scholar E (2007) Neomycin. in xpharm: The Comprehensive Pharmacology Reference. https:\/\/doi.org\/10.1016\/B978-008055232-3.62258-5","DOI":"10.1016\/B978-008055232-3.62258-5"},{"key":"10452_CR66","first-page":"97","volume":"171","author":"JE Sykes","year":"2013","unstructured":"Sykes JE, Papich MG (2013) Antiprotozoal drugs. Canine Feline Infect Dis 171:97\u2013104","journal-title":"Canine Feline Infect Dis"},{"issue":"4","key":"10452_CR67","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski CA (2004) Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 1(4):337\u2013341","journal-title":"Drug Discov Today Technol"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-022-10452-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-022-10452-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-022-10452-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T10:25:13Z","timestamp":1683541513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-022-10452-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10452"],"URL":"https:\/\/doi.org\/10.1007\/s11030-022-10452-2","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]},"assertion":[{"value":"6 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}